14/05/2026 Filing of Gazyva for additional indication of Idiopathic Nephrotic Syndrome Filing of Gazyva for additional indication of Idiopathic Nephrotic Syndrome (Ref) Chugai Pharmaceutical and Nippon Shinyaku announced that Chugai had filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for Gazyva® (obinutuzumab; anti-CD20) for intravenous infusion 1000 mg for an additional indication of idiopathic nephrotic syndrome (INS). The filing was ba

21/04/2026 FDA accepted application for Roche’s Gazyva for the treatment of SLE Cristcot announced FDA acceptance of NDA for ngHCA for treatment of UC of the Rectum AstraZeneca announced Phase 3 results for ravulizumab for IgA Nephropathy FDA accepted application for Roche’s Gazyva for the treatment of SLE ( Ref ) Roche announced that the US FDA had accepted a supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment o

16/02/2026 Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy ( Ref ) Roche announced positive results from the Phase 3 MAJESTY/ NCT04629248 study which evaluated the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab; anti-CD20) in patients with primary membranous nephropathy The study met its primary endpoint of complete remission at t